159 related articles for article (PubMed ID: 19906270)
21. Type 1 diabetes and epilepsy: more than a casual association?
Mancardi MM; Striano P; Giannattasio A; Baglietto MG; Errichiello L; Zara F; Prato G; Minuto N; Veneselli E; Lorini R; D'Annunzio G
Epilepsia; 2010 Feb; 51(2):320-1. PubMed ID: 20331700
[No Abstract] [Full Text] [Related]
22. Pearls & oy-sters: Hashimoto encephalopathy.
Afshari M; Afshari ZS; Schuele SU
Neurology; 2012 May; 78(22):e134-7. PubMed ID: 22641407
[No Abstract] [Full Text] [Related]
23. Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase.
Ishida K; Mitoma H; Song SY; Uchihara T; Inaba A; Eguchi S; Kobayashi T; Mizusawa H
Ann Neurol; 1999 Aug; 46(2):263-7. PubMed ID: 10443895
[TBL] [Abstract][Full Text] [Related]
24. Opsoclonus-myoclonus-ataxia syndrome with autoantibodies to glutamic acid decarboxylase.
Markakis I; Alexiou E; Xifaras M; Gekas G; Rombos A
Clin Neurol Neurosurg; 2008 Jun; 110(6):619-21. PubMed ID: 18433986
[TBL] [Abstract][Full Text] [Related]
25. Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus.
Kanter IC; Huttner HB; Staykov D; Biermann T; Struffert T; Kerling F; Hilz MJ; Schellinger PD; Schwab S; Bardutzky J
Epilepsia; 2008 May; 49(5):914-20. PubMed ID: 18177354
[TBL] [Abstract][Full Text] [Related]
26. A patient with type 1 diabetes mellitus and cerebellar ataxia associated with high titer of circulating anti-glutamic acid decarboxylase antibodies.
Iwasaki H; Sato R; Shichiri M; Hirata Y
Endocr J; 2001 Apr; 48(2):261-8. PubMed ID: 11456277
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome.
Dinkel K; Meinck HM; Jury KM; Karges W; Richter W
Ann Neurol; 1998 Aug; 44(2):194-201. PubMed ID: 9708541
[TBL] [Abstract][Full Text] [Related]
28. Spontaneous downbeat nystagmus as a clue for the diagnosis of ataxia associated with anti-GAD antibodies.
Vale TC; Pedroso JL; Alquéres RA; Dutra LA; Barsottini OG
J Neurol Sci; 2015 Dec; 359(1-2):21-3. PubMed ID: 26671081
[TBL] [Abstract][Full Text] [Related]
29. Anti-GAD Antibody, Seizures, Cerebellar Ataxias and Vitiligo: A Diagnostic Challenge.
Flores-Cantu H; Camara-Lemarroy CR; Calderon-Hernandez HJ; Zapata-Rivera MA; Villareal-Perez JZ; Villareal-Velazquez HJ
Cerebellum; 2015 Jun; 14(3):375-7. PubMed ID: 25575726
[No Abstract] [Full Text] [Related]
30. Clinical characteristics of patients with cerebellar ataxia associated with anti-GAD antibodies.
Aguiar TS; Fragoso A; Albuquerque CR; Teixeira PF; Souza MV; Zajdenverg L; Alves-Leon SV; Rodacki M; Lima MA
Arq Neuropsiquiatr; 2017 Mar; 75(3):142-146. PubMed ID: 28355320
[TBL] [Abstract][Full Text] [Related]
31. Cerebellar ataxia associated with anti-glutamic acid decarboxylase autoantibodies.
Vianello M; Tavolato B; Armani M; Giometto B
Cerebellum; 2003; 2(1):77-9. PubMed ID: 12882238
[TBL] [Abstract][Full Text] [Related]
32. Experience with immunotherapy in 3 patients with cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies.
Rouco I; Hurtado P; Castaño L; Zarranz JJ
Neurologia; 2015 May; 30(4):247-9. PubMed ID: 24075582
[No Abstract] [Full Text] [Related]
33. Efficacy of oral corticosteroids therapy in anti-glutamic acid decarboxylase antibodies cerebellar ataxia.
di Biase L; Assenza G; Iorio R; Melgari JM; Salomone G; Marano M; Muda AO; Di Lazzaro V
Parkinsonism Relat Disord; 2016 Sep; 30():78-80. PubMed ID: 27236207
[No Abstract] [Full Text] [Related]
34. Therapeutic plasma exchange and immunosuppressive therapy in a patient with anti-GAD antibody-related epilepsy: quantification of the antibody response.
Farooqi MS; Lai Y; Lancaster E; Schmitt SE; Sachais BS
J Clin Apher; 2015 Feb; 30(1):8-14. PubMed ID: 24961613
[TBL] [Abstract][Full Text] [Related]
35. Antibody-phenotype correlation in stiff-person syndrome.
Evoli A
Neurology; 2008 Dec; 71(24):1938-9. PubMed ID: 18971446
[No Abstract] [Full Text] [Related]
36. Cerebellar ataxia with glutamic acid decarboxylase autoantibodies.
Abele M; Weller M; Mescheriakov S; Bürk K; Dichgans J; Klockgether T
Neurology; 1999 Mar; 52(4):857-9. PubMed ID: 10078741
[TBL] [Abstract][Full Text] [Related]
37. Autoantibody-mediated disorders of the central nervous system.
Irani S; Lang B
Autoimmunity; 2008 Feb; 41(1):55-65. PubMed ID: 18176865
[TBL] [Abstract][Full Text] [Related]
38. Progressive cerebellar ataxia and new-onset diabetes.
Kong MF; Glibert G; Baleanu F; Karmali R
Lancet; 2014 Jan; 383(9912):186. PubMed ID: 24411971
[No Abstract] [Full Text] [Related]
39. Non-convulsive status epilepticus associated with glutamic acid decarboxylase antibody.
Cikrikçili U; Ulusoy C; Turan S; Yildiz S; Bilgiç B; Hanagasi H; Baykan B; Tüzün E; Gürvit H
Clin EEG Neurosci; 2013 Jul; 44(3):232-6. PubMed ID: 23820312
[TBL] [Abstract][Full Text] [Related]
40. Disabling Central Paroxysmal Positioning Upbeat Nystagmus and Vertigo Associated With the Presence of Anti-Glutamic Acid Decarboxylase Antibodies.
Martins AI; Carvalho JN; Amorim AM; Geraldo A; Eggenberger E; Lemos J
J Neuroophthalmol; 2018 Mar; 38(1):32-35. PubMed ID: 28767521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
